A Phase 1 Study of Autologous Dendritic Cell Immunotherapy in Patients With mCRPC

September 15, 2026 updated by: Pharmicell Co., Ltd.

An Open Label, Single-center, Phase 1 Study to Evaluate the Safety of Cancer Immunotherapy With Autologous Dendritic Cells in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

The goal of this clinical trial was to evaluate the safety of Cellgram-DC-PC, an autologous dendritic cell-based cancer immunotherapy, in patients with metastatic castration-resistant prostate cancer (mCRPC).

Study Overview

Status

Terminated

Conditions

Intervention / Treatment

Detailed Description

Cellgram-DC-PC is an autologous dendritic cell-based cancer immunotherapy developed for patients with metastatic castration-resistant prostate cancer (mCRPC). This was a Phase 1, single-center, open-label clinical trial designed to characterize the safety profile of Cellgram-DC-PC following administration in patients with mCRPC.

Study Type

Interventional

Enrollment (Actual)

3

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

19 years to 79 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Male

Description

Inclusion Criteria:

  1. 19 and under 80 years

  2. Histologically confirmed prostate adenocarcinoma

  3. Patients with stage M1a or M1b with extrapelvic lymph nodes and bone metastases

  4. Patients diagnosed with castration-resistant prostate cancer after failure of male hormone deprivation therapy (Castrate levels of testosterone <50 ng/dL) and If either a or b is satisfied:

    1. Biochemical progression: Prostate Specific Antigen (PSA) increases three times in a row at 1 week intervals, two 50% increases compared to the lowest point, PSA> 2ng/mL, or
    2. Radiological progression: appearance of new lesions; 2 or more new lesions on the bone scan
  5. Asymptomatic or mild patients after previous treatment

    1. Patients who have not used narcotic analgesics within 21 days prior to enrollment
    2. Patients with an average weekly pain of less than 4 on the Visual Analogue Scale(VAS) (out of 10)
  6. Combination of Luteinizing hormone-releasing hormone(LHRH) analogs (leuprolide (Lupron, Viadur, Eligard) and goserelin (Zoladex, etc.) for the inhibition of gonadotropin is allowed

  7. Whole body performance status: European Cooperative Oncology Group(ECOG) 0~1

  8. Patients whose life expectancy is at least 6 months or longer

  9. Hb ≥ 8.0g/dL, Absolute Neutrophil Count(ANC) ≥ 1,500/mm3, Platelets ≥ 100,000/mm3

  10. Serum Creatinine ≤ 2.0 x Upper Limit of Normal(ULN) or Calculated Creatinine Clearance > 30mL/min

  11. Total Bilirubin ≤ 1.5 x ULN or Direct bilirubin ≤ ULN, Aminotransferase (AST)/Alanine aminotransferase(ALT) <2.5 x ULN

  12. Patients who did not receive surgery, radiation therapy, or immunotherapy within the last 6 weeks and recovered from side effects

  13. Patients who agreed to use medically recognized contraceptive methods during the clinical trial participation period

  14. Patients who voluntarily participated in clinical trials and signed the Informed Contents Form (ICF)

Exclusion Criteria:

  1. Patients who have a local recurrence and are scheduled for local treatment.
  2. Patients with malignant tumors other than non-melanoma skin cancer in the past 3 years
  3. Patients with visceral metastases (metastases to the lungs, liver, adrenal glands, peritoneum, brain, etc.)
  4. Patients who previously received anti-tumor immunotherapy (anti-PD1, anti-PDL1 or anti-PDL2, etc.) or participated in immunotherapy-related clinical trials
  5. Patients with active autoimmune diseases requiring systemic immunosuppression treatment (e.g., immunosuppressants such as cyclosporin A or azathioprine or steroids for disease control)
  6. Patients with medical conditions requiring continuous or intermittent administration of systemic steroids or immunosuppressants
  7. Patients who received blood products (limited to whole blood products) within 4 weeks of screening criteria, or patients who received colony stimulating factors (Colony Stimulating Factor or recombinant Erythropoietin)
  8. Patients with a history of organ or hematopoietic stem cell transplantation
  9. Patients with acute or chronic infections requiring systemic treatment
  10. Patients known to be infected with human immunodeficiency virus (HIV)/serum positive
  11. Patients with active hepatitis A, B or C
  12. Patients with untreated syphilis (Fluorescent Treponemal Antibody Absorption Test (FTA-ABS) Immunoglobulin M positive patients)
  13. Patients expected to require therapeutic biotherapy or immunotherapy
  14. Patients who received live virus vaccines (e.g. measles, mumps, rubella, chickenpox, yellow fever, rabies, Bacillus Calmette-Guerin (BCG), oral typhoid vaccine, Flu-Mist, etc.) within 30 days
  15. Patients with a history of anaphylaxis to gentamicin
  16. Others, if the person in charge of the study determines that it is not suitable for the clinical trial

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Cellgram-DC-PC

Participants received Cellgram-DC-PC by subcutaneous injection near the inguinal lymph nodes.

Patients received three subcutaneous injections of Cellgram-DC-PC (autologous dendritic cells) near the inguinal lymph nodes at Weeks 0, 2, and 4.

Other Names:
  • Autologous dendritic cell anti-cancer immune cell therapy for prostate cancer treatment

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Adverse Event
Time Frame: From informed consent to the end of treatment at Week 28.

Adverse events (AEs) were assessed for severity according to the Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.

From informed consent to the end of treatment at Week 28.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Immune Response
Time Frame: At baseline (Week 0), Week 4, Week 8, Week 16, and Week 28.

Tumor antigen-specific immune responses were evaluated by measuring changes in serum IFN-γ and IL-12 levels and antigen-specific T-cell responses following administration of the investigational product.

At baseline (Week 0), Week 4, Week 8, Week 16, and Week 28.
Change in Prostate-Specific Antigen (PSA)
Time Frame: At baseline (Week 0), Week 2, Week 4, Week 8, Week 16, and Week 28.

Exploratory efficacy was evaluated by measuring changes in prostate-specific antigen (PSA) levels from pre-treatment (Week 0) to post-treatment assessment.

At baseline (Week 0), Week 2, Week 4, Week 8, Week 16, and Week 28.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: BUMJIN LIM, Ph.D, Asan Medical Center

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 5, 2021

Primary Completion (Actual)

February 15, 2022

Study Completion (Actual)

June 30, 2022

Study Registration Dates

First Submitted

October 22, 2020

First Submitted That Met QC Criteria

November 2, 2020

First Posted (Actual)

November 4, 2020

Study Record Updates

Last Update Posted (Actual)

September 21, 2026

Last Update Submitted That Met QC Criteria

September 15, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • PMC-DC-01

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Individual participant data will not be made available to other researchers.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.